Oncotelic Therapeutics, Inc. 8-K

What Happened

• On December 22, 2025, Oncotelic Therapeutics, Inc. (OTLC) issued a press release announcing open access to PDAOAI, its proprietary evidence‑interrogation platform designed to extract biologically meaningful signals from large, complex biomedical datasets without training bespoke large language models on proprietary data.
• The company also said it is providing researchers access to a TGF‑β literature corpus — comprising more than 125,000 PubMed abstracts — through a dedicated Discord research channel. A copy of the press release is attached as Exhibit 99.1 to the Form 8‑K.

Key Details

• Press release date: December 22, 2025 (filed on Form 8‑K 12/23/2025).
• TGF‑β literature corpus size: more than 125,000 PubMed abstracts.
• Access channel: Dedicated Discord research channel for researchers.
• The filing includes standard forward‑looking statements and a disclaimer that the Section 8.01 information is being furnished, not filed, under SEC rules.

Why It Matters

• For investors, the announcement documents a strategic move to make Oncotelic’s data‑analysis technology and a large disease‑focused literature corpus publicly accessible to researchers, which could increase external engagement with the company’s platform and related research activities.
• The filing reiterates forward‑looking language and legal disclaimers (including that the information in Section 8.01 is furnished, not filed), so investors should treat forward‑looking statements cautiously and refer to the company’s periodic reports for material financial or clinical developments.